vTv Therapeutics Inc (OQ:VTVT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 3980 Premier Dr, Suite 310
HIGH POINT NC 27265
Tel: N/A
Website: https://vtvtherapeutics.com
IR: See website
<
Key People
Paul Jai Sekhri
President, Chief Executive Officer, Director
Steven Tuch
Chief Financial Officer
Richard S. Nelson
Executive Vice President - Corporate Development, Director
Barry Brown
Chief Accounting Officer
Thomas Strack
Chief Medical Officer
 
Business Overview
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.
Financial Overview
For the fiscal year ended 31 December 2023, vTv Therapeutics Inc revenues decreased from $2M to $0K. Net loss increased 6% to $20.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development - Balancing increase of 10% to $13.2M (expense), Other income (expense) - related party decrease of 39% to $574K (income).
Employees: 16 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $67.51M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$25.41M as of Dec 31, 2023
Net annual income (TTM): -$20.25M as of Dec 31, 2023
Free cash flow (TTM): -$19.08M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 2,662,322 as of Mar 13, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.